![](https://www.aiche.org/sites/default/files/styles/ache_portrait_no-up-scale_nocrop/public/images/bio/ioscani.png?itok=YagdiVlE)
Ioscani leads the Animal Cell Technology Group (ACTG) at the School of Chemical & Bioprocess Engineering, University College Dublin. UCD’s ACTG is a multidisciplinary team that combines advanced experimentation and computational strategies to optimise the production of biopharmaceuticals, including monoclonal antibodies (mAbs) and gene therapy viral vectors.
Experimentally, ACTG develops and deploys synthetic biology and cell engineering strategies to enhance the productivity and quality of biopharmaceuticals derived from cell culture bioprocesses. Computationally, ACTG works on developing multi-scale mathematical models that describe cell culture dynamics, therapeutic protein glycosylation, cellular metabolic fluxes and full-scale integrated continuous bioprocesses.
Ioscani graduated with a BE in Chemical Engineering from the National Autonomous University of Mexico (UNAM) in 2006. He received his MSc in Advanced Chemical Engineering with Biotechnology in 2008 and was awarded his PhD in 2013, both from Imperial College London. Before joining the UCD School of Chemical & Bioprocess Engineering as Assistant Professor in 2014, Ioscani worked as a Postdoctoral Research Associate with Dr. Cleo Kontoravdi and Dr. Karen Polizzi at Imperial College London developing an integrated computational/experimental framework to control therapeutic mAb glycosylation.